Saving changes...

Done

Error

2018 ACCP Virtual Journal Club November | Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment

2018 ACCP Virtual Journal Club November | Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment

2018 ACCP Virtual Journal Club November | Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment

William D. Figg, PharmD, Senior Investigator
William D. Figg, PharmD, Senior Investigator
on behalf of American College of Clinical Pharmacology

$20.00 $ 20.00 $ 20.00

$20.00 $ 20.00 $ 20.00

$ 20.00 $ 20.00 $ 20.00
$ 20.00 $ 20.00 $ 20.00
Normal Price: $20.00 $20.00

Review:

Launch date: 29 Nov 2018
Expiry Date: 28 Nov 2021

Last updated: 18 Dec 2018

Reference: 192956

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

The goal of this activity is to provide a comprehensive overview of clinically-relevant biomarkers and molecular profiling platforms in precision oncology medicine to optimize cancer treatment outcomes.

Objectives

Describe the difference between prognostic and predictive oncology biomarkers
After completing this activity, the learner will be able to describe the difference between prognostic and predictive oncology biomarkers.
Discuss prognostic biomarkers including drug-target pairs and their companion diagnostic tests
After completing this activity, the learner will be able to discuss prognostic biomarkers including drug-target pairs and their companion diagnostic tests.
Explain how drug sensitivity/resistance, metabolism and toxicity relate to predictive biomarkers
After completing this activity, the learner will be able to explain how drug sensitivity/resistance, metabolism and toxicity relate to predictive biomarkers.
List current efforts to improve the advancing field of precision oncology medicine
After completing this activity, the learner will be able to list current efforts to improve the advancing field of precision oncology medicine.
William D. Figg, PharmD, Senior Investigator

Author Information Play Video Bio

William D. Figg, PharmD, Senior Investigator
on behalf of American College of Clinical Pharmacology

In the 1960s, a group of eminent physicians formulated the concept of an organization dedicated to a new branch of pharmacology that dealt with the effectiveness and safety of drugs in man. As a result of their efforts, the American College of Clinical Pharmacology (ACCP) was founded on September 11, 1969. Today, ACCP consists of a full spectrum of clinical pharmacology professionals from academia, industry, government and clinical settings who span the scope from research and drug development to patient-related care and who remain dedicated to advancing clinical pharmacology with the ultimate goal of enhancing patient care.

As an organization whose primary role is education, ACCP does not concentrate on any one aspect of the discipline. Rather, it seeks to address the educational needs of its diverse membership and all healthcare professionals, covering a range of topics that span the entire area of the interaction between drugs and humans. These areas include, but are not limited to, pharmaceutical chemistry, biochemistry, drug metabolism, pharmacokinetics, pharmacodynamics, pharmacometrics, pharmacogenomics clinical pharmacology practice in the outpatient and inpatient settings, human toxicology, drug interactions and clinical drug trials. The diversity of ACCP is expressed not only in the composition of its membership, but also in its leadership. Maintaining a balance of elected Regents and Officers from all pertinent professional backgrounds ensures that ACCP remains attuned to the needs of all professionals engaged in the practice of or with a strong interest in clinical pharmacology, from the research laboratory (academic and industrial) to the classroom, and from clinical trials to improved patient care.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Continuing Medical Education (ACCME)
  • 1.00 Credits
  • Accreditation Council for Pharmacy Education (ACPE)
  • 1.00 Hours -
    Exam Pass Rate: 75

Faculty and Disclosures

William D. Figg,  PharmD, Senior Investigator, Natl Cancer Inst of the Natl Inst of Health, Molecular and Clinical Pharmacology Program

William D. Figg, PharmD, Senior Investigator, Natl Cancer Inst of the Natl Inst of Health, Molecular and Clinical Pharmacology Program

Reports nothing to disclose.
Chakradhar Lagishetty, PhD, Clinical Pharmacologist, GlaxoSmithKline, Clinical Pharmacology & Modeling Simulation

Chakradhar Lagishetty, PhD, Clinical Pharmacologist, GlaxoSmithKline, Clinical Pharmacology & Modeling Simulation

Has nothing to disclose related to this topic.
Lawrence Cohen, PharmD, FCCP, FCPP, FCP, Professor, Univ of North Texas System Coll of Pharmacy, Dept of Pharmacotherapy

Lawrence Cohen, PharmD, FCCP, FCPP, FCP, Professor, Univ of North Texas System Coll of Pharmacy, Dept of Pharmacotherapy

Has nothing to disclose related to this topic.
Jonathan Constance, PhD, Assistant Professor, Univ of Utah, Dept of Pediatrics

Jonathan Constance, PhD, Assistant Professor, Univ of Utah, Dept of Pediatrics

Has nothing to disclose.

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error